Company intelligence / Profile preview

Endosense

Geneva (Meyrin), Genève, Switzerland

Ownership: Private
Development stage: Other

Overview

Endosense developed the TactiCath force-sensing ablation catheter, which was CE Mark approved for atrial fibrillation and supraventricular tachycardia. Its clinical trials (TOCCATA, EFFICAS I/II, TOCCASTAR) demonstrated improved safety and reduced AF recurrence by enabling real-time contact-force monitoring during ablation procedures.

Therapeutic areas: Cardiovascular
Modalities: Device
Industry: Therapeutic Medical Devices

Partnerships

St. Jude Medical

Beyond the preview

Go deeper on Endosense.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Endosense.

Explore the full profile